Dame Emma Walmsley, departing chief executive of GSK, has emphasised the critical need for further improvements within the United Kingdom’s life sciences commercial environment. Speaking following the recent UK United
All posts tagged in Life Sciences
18Articles
The United Kingdom is poised to provide NHS patients with access to new medicines previously deemed unaffordable under a sweeping agreement with the United States. Under the deal, NHS expenditure
The UK is facing mounting pressure from the United States to reform its drug pricing policies, with the US ambassador, Warren Stephens, delivering a stark ultimatum to government officials and
More than 200 chief executives from the world of British biotechnology have united in a passionate appeal to the Chancellor, warning that proposed increases in taxes or business rates for
The UK pharmaceutical sector, long celebrated as a linchpin of the British economy, now faces an unprecedented crisis following the imposition of sweeping new tariffs by Donald Trump. In a
Britain’s pharmaceutical sector has been thrust into sharp focus as the government pledges urgent action to resolve a standoff with multinational drug companies. In the aftermath of several high-profile withdrawals
AstraZeneca, the United Kingdom’s most valuable listed business, has announced a pause on its planned £200 million expansion at the Cambridge research hub, dealing a substantial setback to the government’s
The United Kingdom is facing a stark decline in its attractiveness to global investors in the life sciences and pharmaceutical industries, with industry leaders warning the nation is falling behind
Merck, the renowned US pharmaceuticals giant known as MSD across Europe, has abandoned plans for a £1 billion research centre in London—a significant blow for the UK life sciences sector.
Wes Streeting, the new health secretary, has escalated his confrontation with leading pharmaceutical firms over the soaring cost of medicines and its impact on the UK’s broader life sciences sector.
Shares in Oxford Nanopore surged as the FTSE 250 gene-sequencing specialist reported stronger than expected sales for the first half of 2025. The company expects to post revenues of around
In a significant shift for the UK’s life sciences sector, Syncona, the Wellcome Trust-backed FTSE 250 investment company, has revealed plans to implement an orderly wind-down of its portfolio assets.
Investment in Britain’s vital life sciences sector is under threat due to a deteriorating commercial environment. Senior executives from major pharmaceutical companies, including Johnson & Johnson, are voicing concerns that
The recent decision by pharmaceutical giant AstraZeneca to abandon its £450 million investment plan in Liverpool has sparked serious concerns about Britain’s ability to attract and retain major corporate investments.
British pharmaceutical giant AstraZeneca has abandoned its £450 million expansion plans for its vaccine manufacturing facility in Speke, Liverpool, delivering a significant blow to the UK’s life sciences sector. The
A critical £450 million investment by pharmaceutical giant AstraZeneca in a new vaccines facility in Speke, Liverpool, has encountered significant delays due to prolonged government deliberations on support measures. The
- 1
- 2
